Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687076 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
NCT00687076 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 102 participants.
The verdict
NCT00687076, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
Study Summary
Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits. PAD develops most often in arteries in the legs, which can result in reduced blood flow to the legs and feet, occasionally causing leg pain and fatigue. Early identification of PAD and treatment with lifestyle changes or medications can help to keep legs healthy and lower risk for heart attack and stroke, but endovascular or surgical procedures may be necessary for people with severe PAD. Even after endovascular intervention, PAD symptoms must be continually monitored to prevent the development and progression of blockages in the arteries. The best approach for monitoring symptoms is still undetermined. This study will compare the effectiveness of an intensive combination of lipid modifying medications versus standard lipid modifying medications in treating people with significant PAD who have had an endovascular intervention.
Interventions
- DRUG Aspirin
- DRUG Ezetimibe
- BEHAVIORAL Standard care
- DRUG Niaspan
- DRUG Statin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2004-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687076
The ClinicalTrials.gov registry entry for NCT00687076 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aspirin is the first listed.
NCT00687076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00687076 about?
NCT00687076 is a clinical study titled "Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)". Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits. PAD develops most often in arteries in the legs, which can result in reduced blood flow to the legs and feet, occasionally causing leg pain and fatigue. Early identific...
What is the current status of trial NCT00687076?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2004-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00687076?
The interventions under investigation include: Aspirin (DRUG), Ezetimibe (DRUG), Standard care (BEHAVIORAL), Niaspan (DRUG), Statin therapy (DRUG).
Who is sponsoring clinical trial NCT00687076?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.